甲胺诱导的异性间歇性肺部疾病
Sami M Alyami1, Sarah K Alrasheed1, Bashayer A Albogami1
1Pulmonary Medicine, King Abdulaziz Medical City, Riyadh, SAU.
Cureus
|June 1, 2023
概括
甲福明是一种常见的糖尿病药物,当单独使用时很少会引起埃索诺菲尔间歇性肺病 (ILD). 这一案例突出了独特的不良反应,强调了在出现呼吸系统症状的患者中需要保持警.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 内部医学 内部医学
背景情况:
- 甲福明是一种第一线口服低血糖药,用于治疗2型糖尿病.
- 虽然通常是安全的,但甲福明可以引起各种副作用,其对肺部的影响仍在争论中.
- 以前的报道已经将甲福明组合与间歇性肺病联系起来,但单一治疗的作用不太清楚.
研究的目的:
- 报告一种罕见的异性间歇性肺病 (ILD) 病例,仅由甲福林引起.
- 突出甲福明作为潜在的唯一诱导eosinophilic肺炎的药物.
主要方法:
- 一个64岁的男性患者的病例报告,患有渐进性呼吸障碍.
- 诊断工作包括肺功能测试 (PFT),高分辨率胸部计算机断层扫描 (HRCT) 和带支气管支气管洗 (BAL) 的支气管镜检查.
- 排除了其他已知的异性肺炎原因.
主要成果:
- 这名患者被诊断出患有异性间歇性肺病 (ILD).
- 甲胺被确定为唯一的致病剂.
- 在停止使用甲福明后,呼吸道症状显著改善.
结论:
- 甲胺,即使是单一的药物,也可以诱导eosinophilic肺炎.
- 这代表了第一次报告的甲福明单一治疗导致这种特定肺部疾病的病例.
- 临床医生应考虑在出现不明原因呼吸道症状的患者中考虑甲福林诱导的ILD.
相关概念视频
Oral Hypoglycemic Agents: Biguanides and Glitazones
241
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
241
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
361
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
361
Antiasthma Drugs: Leukotriene Modifiers
379
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
379
Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
Antiasthma Drugs: Methylxanthines
285
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
285


